banner-AreeTerapeutiche



LITERATURE UPDATE


IN QUESTA SEZIONE È DISPONIBILE UNA SELEZIONE DI ARTICOLI
SUDDIVISA PER AREE TERAPEUTICHE


Cliccando sul link al titolo di ogni articolo sarà possibile leggere l’abstract o l’articolo in versione integrale
a seconda delle modalità di divulgazione scelte dai titolari dei diritti.

 

 

DEPRESSION

  1. Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials. 

    Yang X, Chen X, Fu Y, Luo Q, Du L, Qiu H, Qiu T, Zhang L, Meng H. 

    Neuropsychiatr Dis Treat. 2018 May 21;14:1297-1305. doi: 10.2147/NDT.S157550. eCollection 2018. 

  2. The association of folate and depression: A meta-analysis.

    Bender A, Hagan KE, Kingston N.

    J Psychiatr Res. 2017 Dec;95:9-18. doi: 10.1016/j.jpsychires.2017.07.019. Epub 2017 Jul 22. Review.

  3. S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research.

    Sharma A, Gerbarg P, Bottiglieri T, Massoumi L, Carpenter LL, Lavretsky H, Muskin PR, Brown RP, Mischoulon D; as Work Group of the American Psychiatric Association Council on Research.

    J Clin Psychiatry. 2017 Jun;78(6):e656-e667. doi: 10.4088/JCP.16r11113. Review.

  4. Effects of chronic l-theanine administration in patients with major depressive disorder: an open-label study.

    Hidese S, Ota M, Wakabayashi C, Noda T, Ozawa H, Okubo T, Kunugi H.

    Acta Neuropsychiatr. 2017 Apr;29(2):72-79. doi: 10.1017/neu.2016.33. Epub 2016 Jul 11.

  5. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments.

    Ravindran AV, Balneaves LG, Faulkner G, Ortiz A, McIntosh D, Morehouse RL, Ravindran L, Yatham LN, Kennedy SH, Lam RW, MacQueen GM, Milev RV, Parikh SV; CANMAT Depression Work Group.

    Can J Psychiatry. 2016 Sep;61(9):576-87. doi: 10.1177/0706743716660290. Epub 2016 Aug 2. Review.

  6. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.

    Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH.

    Am J Psychiatry. 2016 Jun 1;173(6):575-87. doi: 10.1176/appi.ajp.2016.15091228. Epub 2016 Apr 26. Review.

  7. N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis.

    Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M.

    J Clin Psychiatry. 2016 Apr;77(4):e457-66. doi: 10.4088/JCP.15r09984. Review.

  8. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.

    Mocking RJ, Harmsen I, Assies J, Koeter MW, Ruhé HG, Schene AH.

    Transl Psychiatry. 2016 Mar 15;6:e756. doi: 10.1038/tp.2016.29.

  9. Cognitive remission: a novel objective for the treatment of major depression?

    Bortolato B, Miskowiak KW, Köhler CA, Maes M, Fernandes BS, Berk M, Carvalho AF.

    BMC Med. 2016 Jan 22;14:9. doi: 10.1186/s12916-016-0560-3. Review.

HEADACHES

  1. Paediatric migraine: evidence-based management and future directions.
    Orr SL, Kabbouche MA, O'Brien HL, Kacperski J, Powers SW, Hershey AD.
    Nat Rev Neurol. 2018 Sep;14(9):515-527. doi: 10.1038/s41582-018-0042-7. Review.
  2. Energy Metabolism Impairment in Migraine.
    Cevoli S, Favoni V, Cortelli P.
    Curr Med Chem. 2018 Jun 22. doi: 10.2174/0929867325666180622154411. [Epub ahead of print]
  3. Double-blind placebo-controlled randomized clinical trial of ginger ( Zingiber officinale Rosc.) addition in migraine acute treatment.
    Martins LB, Rodrigues AMDS, Rodrigues DF, Dos Santos LC, Teixeira AL, Ferreira AVM.
    Cephalalgia. 2018 Jan 1:333102418776016. doi: 10.1177/0333102418776016. [Epub ahead of print]
  4. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.
    [No authors listed]
    Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202. No abstract available.
  5. Nutraceuticals in Acute and Prophylactic Treatment of Migraine.
    Daniel O, Mauskop A.
    Curr Treat Options Neurol. 2016 Apr;18(4):14. doi: 10.1007/s11940-016-0398-1.
  6. Feverfew for preventing migraine.
    Wider B, Pittler MH, Ernst E.
    Cochrane Database Syst Rev. 2015 Apr 20;4:CD002286. [Epub ahead of print]

DEMENTIA

  1. Anti-inflammatory Effects of Homotaurine in Patients With Amnestic Mild Cognitive Impairment.
    Bossù P, Salani F, Ciaramella A, Sacchinelli E, Mosca A, Banaj N, Assogna F, Orfei MD, Caltagirone C, Gianni W, Spalletta G.
    Front Aging Neurosci. 2018 Nov 2;10:285. doi: 10.3389/fnagi.2018.00285. eCollection 2018.
  2. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
    Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhnálek M, Yu JY, Tolar M.
    CNS Drugs. 2018 Sep;32(9):849-861. doi: 10.1007/s40263-018-0554-0. Erratum in: CNS Drugs. 2018 Dec;32(12):1185.
  3. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Wang P, Shen L, Tolar M.
    J Prev Alzheimers Dis. 2017;4(3):149-156. doi: 10.14283/jpad.2017.26.
  4. Defeating Alzheimer's disease and other dementias: a priority for European science and society.
    Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, Iqbal K, Jessen F, Johansson G, Jönsson L, Kivipelto M, Knapp M, Mangialasche F, Melis R, Nordberg A, Rikkert MO, Qiu C, Sakmar TP, Scheltens P, Schneider LS, Sperling R, Tjernberg LO, Waldemar G, Wimo A, Zetterberg H.
    Lancet Neurol. 2016 Apr;15(5):455-532. doi: 10.1016/S1474-4422(16)00062-4. Review. No abstract available.
  5. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
    Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR Jr; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA.
    Alzheimers Dement. 2016 Mar;12(3):292-323. doi: 10.1016/j.jalz.2016.02.002. Review.
  6. Homotaurine Effects on Hippocampal Volume Loss and Episodic Memory in Amnestic Mild Cognitive Impairment.
    Spalletta G, Cravello L, Gianni W, Piras F, Iorio M, Cacciari C, Casini AR, Chiapponi C, Sancesario G, Fratangeli C, Orfei MD, Caltagirone C, Piras F.
    J Alzheimers Dis. 2016;50(3):807-16. doi: 10.3233/JAD-150484.
  7. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.
    Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL.
    Lancet Neurol. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0. Erratum in: Lancet Neurol. 2014 Aug;13(8):757.

EPILEPSY

  1. Switch From Originator to Equivalent Drug in the Era of Generic Antiepileptic Drugs: Study of Keppra Versus Epitiram Clinical Equivalence.
    Fanella M, Morano A, Fattouch J, Albini M, Basili LM, Casciato S, Manfredi M, Giallonardo AT, Di Bonaventura C.
    Clin Neuropharmacol. 2017 Nov/Dec;40(6):239-242. doi: 10.1097/WNF.0000000000000250.
  2. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology.
    Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM.
    Epilepsia. 2017 Apr;58(4):512-521. doi: 10.1111/epi.13709. Epub 2017 Mar 8.
  3. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.
    Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshé SL, Peltola J, Roulet Perez E, Scheffer IE, Zuberi SM.
    Epilepsia. 2017 Apr;58(4):522-530. doi: 10.1111/epi.13670. Epub 2017 Mar 8.
  4. Pharmacogenomics in epilepsy.
    Balestrini S, Sisodiya SM.
    Neurosci Lett. 2018 Feb 22;667:27-39. doi: 10.1016/j.neulet.2017.01.014. Epub 2017 Jan 10. Review.
  5. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.
    Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, Mattson R, French JA, Perucca E, Tomson T; ILAE Subcommission on AED Guidelines.
    Epilepsia. 2013 Mar;54(3):551-63. doi: 10.1111/epi.12074. Epub 2013 Jan 25. Review.

CHRONIC PAIN

  1. Observational clinical and nerve conduction study on effects of a nutraceutical combination on painful diabetic distal symmetric sensory-motor neuropathy in patients with diabetes type 1 and type 2.
    Semprini R, Martorana A, Ragonese M, Motta C.
    Minerva Med. 2018 Oct;109(5):358-362. doi: 10.23736/S0026-4806.18.05710-5.
  2. Effects of a nutraceutical combination in patients with chronic lumbosacral radicular pain.
    Geroin C, Tamburin S, Pagano G, Gandolfi M, Tinazzi M.
    Funct Neurol. 2018 Jul/Sept;33(3):125-130.
  3. Neuropathic pain.
    Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, Freeman R, Truini A, Attal N, Finnerup NB, Eccleston C, Kalso E, Bennett DL, Dworkin RH, Raja SN.
    Nat Rev Dis Primers. 2017 Feb 16;3:17002. doi: 10.1038/nrdp.2017.2. Review.
  4. The Dietary Components Carnosic Acid and Carnosol as Neuroprotective Agents: a Mechanistic View.
    de Oliveira MR.
    Mol Neurobiol. 2016 Nov;53(9):6155-6168. doi: 10.1007/s12035-015-9519-1. Epub 2015 Nov 9. Review.
  5. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy.
    Gabrielsson L, Mattsson S, Fowler CJ.
    Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111/bcp.13020. Epub 2016 Jun 29. Review.
  6. Fibromyalgia.
    Häuser W, Ablin J, Fitzcharles MA, Littlejohn G, Luciano JV, Usui C, Walitt B.
    Nat Rev Dis Primers. 2015 Aug 13;1:15022. doi: 10.1038/nrdp.2015.22. Review.
  7. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.
    Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M.
    Lancet Neurol. 2015 Feb;14(2):162-73. doi: 10.1016/S1474-4422(14)70251-0. Epub 2015 Jan 7. Review.
  8. The cannabinoid CB₂ receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain.
    Klauke AL, Racz I, Pradier B, Markert A, Zimmer AM, Gertsch J, Zimmer A.
    Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20. doi: 10.1016/j.euroneuro.2013.10.008. Epub 2013 Oct 22.

PHARMACOGENETIC

  1. A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial.
    Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, Mandelli L, Pae CU, Serretti A.
    Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):469-480. doi: 10.9758/cpn.2018.16.4.469.
  2. The utility of pharmacogenetic testing to support the treatment of bipolar disorder.
    Ielmini M, Poloni N, Caselli I, Espadaler J, Tuson M, Grecchi A, Callegari C.
    Pharmgenomics Pers Med. 2018 Mar 16;11:35-42. doi: 10.2147/PGPM.S160967. eCollection 2018.
  3. Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis.
    Espadaler J, Tuson M, Lopez-Ibor JM, Lopez-Ibor F, Lopez-Ibor MI.
    CNS Spectr. 2017 Aug;22(4):315-324. doi: 10.1017/S1092852915000711. Epub 2016 Apr 21.
  4. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
    Pérez V, Salavert A, Espadaler J, Tuson M, Saiz-Ruiz J, Sáez-Navarro C, Bobes J, Baca-García E, Vieta E, Olivares JM, Rodriguez-Jimenez R, Villagrán JM, Gascón J, Cañete-Crespillo J, Solé M, Saiz PA, Ibáñez Á, de Diego-Adeliño J; AB-GEN Collaborative Group, Menchón JM.
    BMC Psychiatry. 2017 Jul 14;17(1):250. doi: 10.1186/s12888-017-1412-1.
  5. Pharmacogenomics in Pain Management.
    Saba R, Kaye AD, Urman RD.
    Anesthesiol Clin. 2017 Jun;35(2):295-304. doi: 10.1016/j.anclin.2017.01.015. Review.
  6. Pharmacogenomics in the clinic.
    Relling MV, Evans WE.
    Nature. 2015 Oct 15;526(7573):343-50. doi: 10.1038/nature15817. Review.

ANXIETY

  1. GABA-modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence.
    Savage K, Firth J, Stough C, Sarris J.
    Phytother Res. 2018 Jan;32(1):3-18. doi: 10.1002/ptr.5940. Epub 2017 Nov 23. Review.
  2. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis.
    Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P.
    Int Clin Psychopharmacol. 2017 Jan;32(1):49-55. Review.
  3. Neurobiological effects of the green tea constituent theanine and its potential role in the treatment of psychiatric and neurodegenerative disorders.
    Lardner AL.
    Nutr Neurosci. 2014 Jul;17(4):145-55. doi: 10.1179/1476830513Y.0000000079. Epub 2013 Nov 26. Review.
  4. American Skullcap (Scutellaria lateriflora): a randomised, double-blind placebo-controlled crossover study of its effects on mood in healthy volunteers.
    Brock C, Whitehouse J, Tewfik I, Towell T.
    Phytother Res. 2014 May;28(5):692-8. doi: 10.1002/ptr.5044. Epub 2013 Jul 22.
  5. Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.
    Sarris J, McIntyre E, Camfield DA.
    CNS Drugs. 2013 Apr;27(4):301-19. doi: 10.1007/s40263-013-0059-9. Review. Erratum in: CNS Drugs. 2013 Aug;27(8):675. Dosage error in article text.

STROKE AND VASCULAR DEMENTIA

  1. Docosanoids Promote Neurogenesis and Angiogenesis, Blood-Brain Barrier Integrity, Penumbra Protection, and Neurobehavioral Recovery After Experimental Ischemic Stroke.
    Belayev L, Hong SH, Menghani H, Marcell SJ, Obenaus A, Freitas RS, Khoutorova L, Balaszczuk V, Jun B, Oriá RB, Bazan NG.
    Mol Neurobiol. 2018 Aug;55(8):7090-7106. doi: 10.1007/s12035-018-1136-3. Epub 2018 Jun 1.
  2. A Meta-Analysis of Folic Acid in Combination with Anti-Hypertension Drugs in Patients with Hypertension and Hyperhomocysteinemia.
    Wang WW, Wang XS, Zhang ZR, He JC, Xie CL.
    Front Pharmacol. 2017 Aug 31;8:585. doi: 10.3389/fphar.2017.00585. eCollection 2017. Review.
  3. Docosahexaenoic acid regulates vascular endothelial cell function and prevents cardiovascular disease.
    Yamagata K.
    Lipids Health Dis. 2017 Jun 15;16(1):118. doi: 10.1186/s12944-017-0514-6. Review.
  4. Stroke.
    Hankey GJ.
    Lancet. 2017 Feb 11;389(10069):641-654. doi: 10.1016/S0140-6736(16)30962-X. Epub 2016 Sep 13. Review.
  5. Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke.
    Alvarez-Sabín J, Santamarina E, Maisterra O, Jacas C, Molina C, Quintana M.
    Int J Mol Sci. 2016 Mar 16;17(3):390. doi: 10.3390/ijms17030390.
  6. Vascular dementia.
    O'Brien JT, Thomas A.
    Lancet. 2015 Oct 24;386(10004):1698-706. doi: 10.1016/S0140-6736(15)00463-8. Review.
  7. Tramiprosate protects neurons against ischemic stroke by disrupting the interaction between PSD95 and nNOS.
    Wu S, Yue Y, Tian H, Tao L, Wang Y, Xiang J, Wang S, Ding H.
    Neuropharmacology. 2014 Aug;83:107-17. doi: 10.1016/j.neuropharm.2014.04.010. Epub 2014 Apr 24.

SLEEP DISORDERS

  1. Sleep Disorders in the Elderly.
    Yaremchuk K.
    Clin Geriatr Med. 2018 May;34(2):205-216. doi: 10.1016/j.cger.2018.01.008. Review.
  2. GABA-modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence.
    Savage K, Firth J, Stough C, Sarris J.
    Phytother Res. 2018 Jan;32(1):3-18. doi: 10.1002/ptr.5940. Epub 2017 Nov 23. Review.
  3. Association between Benzodiazepine Use and Dementia: Data Mining of Different Medical Databases.
    Takada M, Fujimoto M, Hosomi K.
    Int J Med Sci. 2016 Oct 18;13(11):825-834. eCollection 2016.
  4. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials.
    Xu J, Wang LL, Dammer EB, Li CB, Xu G, Chen SD, Wang G.
    Am J Alzheimers Dis Other Demen. 2015 Aug;30(5):439-47. doi: 10.1177/1533317514568005. Review.
  5. Meta-analysis: melatonin for the treatment of primary sleep disorders.
    Ferracioli-Oda E, Qawasmi A, Bloch MH.
    PLoS One. 2013 May 17;8(5):e63773. doi: 10.1371/journal.pone.0063773. Print 2013.
  6. Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, induces sleep via the benzodiazepine site of GABA(A) receptor in mice.
    Chen CR, Zhou XZ, Luo YJ, Huang ZL, Urade Y, Qu WM.
    Neuropharmacology. 2012 Nov;63(6):1191-9. doi: 10.1016/j.neuropharm.2012.06.031. Epub 2012 Jul 4.
  7. Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database.
    Kunz D, Bineau S, Maman K, Milea D, Toumi M.
    Expert Opin Pharmacother. 2012 Jan;13(1):9-16. doi: 10.1517/14656566.2012.638284. Epub 2011 Nov 22.
  8. The effects of L-theanine (Suntheanine®) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial.
    Lyon MR, Kapoor MP, Juneja LR.
    Altern Med Rev. 2011 Dec;16(4):348-54.

PARKINSON DISEASE

  1. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.
    Chahine LM, Amara AW, Videnovic A.
    Sleep Med Rev. 2017 Oct;35:33-50. doi: 10.1016/j.smrv.2016.08.001. Epub 2016 Aug 31. Review.
  2. Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis.
    Chang Y, Wang LB, Li D, Lei K, Liu SY.
    Ann Med. 2017 Aug;49(5):421-434. doi: 10.1080/07853890.2017.1293285. Epub 2017 Mar 15. Review.
  3. Non-motor features of Parkinson disease.
    Schapira AHV, Chaudhuri KR, Jenner P.
    Nat Rev Neurosci. 2017 Jul;18(7):435-450. doi: 10.1038/nrn.2017.62. Epub 2017 Jun 8. Review. Erratum in: Nat Rev Neurosci. 2017 Aug;18(8):509.
  4. Parkinson disease.
    Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE.
    Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13. Review.
  5. Cognition in Parkinson's Disease.
    O'Callaghan C, Lewis SJG.
    Int Rev Neurobiol. 2017;133:557-583. doi: 10.1016/bs.irn.2017.05.002. Epub 2017 Jun 16. Review.

OBSESSIVE-COMPULSIVE DISORDER

  1. Comparing escitaloipram with sertraline for obsessive and compulsive symptoms in patients with obsessive compulsive disorder: A comparative double blind clinical trial.
    Mowla A, Modarresi F, Dastgheib SA.
    Asian J Psychiatr. 2018 Dec;38:92-95. doi: 10.1016/j.ajp.2017.11.004. Epub 2017 Nov 7.
  2. Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: A systematic review of the clinical evidence.
    Couto JP, Moreira R.
    Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:245-254. doi: 10.1016/j.pnpbp.2018.06.005. Epub 2018 Jun 15. Review.
  3. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment.
    Hirschtritt ME, Bloch MH, Mathews CA.
    JAMA. 2017 Apr 4;317(13):1358-1367. doi: 10.1001/jama.2017.2200. Review.
  4. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.
    Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University, Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O'Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR.
    BMC Psychiatry. 2014;14 Suppl 1:S1. doi: 10.1186/1471-244X-14-S1-S1. Epub 2014 Jul 2. Review.

BIPOLAR DISORDER

  1. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
    Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M.
    Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14.
  2. Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations.
    Wingård L, Bodén R, Brandt L, Tiihonen J, Tanskanen A, Kieler H, Andersen M, Reutfors J.
    J Affect Disord. 2017 Aug 1;217:16-23. doi: 10.1016/j.jad.2017.03.054. Epub 2017 Mar 27.
  3. Omega-3 and Omega-6 Polyunsaturated Fatty Acids in Bipolar Disorder: A Review of Biomarker and Treatment Studies.
    Saunders EF, Ramsden CE, Sherazy MS, Gelenberg AJ, Davis JM, Rapoport SI.
    J Clin Psychiatry. 2016 Oct;77(10):e1301-e1308. doi: 10.4088/JCP.15r09925. Review.
  4. Bipolar disorder.
    Grande I, Berk M, Birmaher B, Vieta E.
    Lancet. 2016 Apr 9;387(10027):1561-72. doi: 10.1016/S0140-6736(15)00241-X. Epub 2015 Sep 18. Review.
  5. Nutrition and Bipolar Depression.
    Beyer JL, Payne ME.
    Psychiatr Clin North Am. 2016 Mar;39(1):75-86. doi: 10.1016/j.psc.2015.10.003. Epub 2015 Dec 23. Review.
  6. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.
    Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS.
    J Affect Disord. 2011 Dec;135(1-3):389-94. doi: 10.1016/j.jad.2011.06.005. Epub 2011 Jun 29.

AUTISM SPECTRUM DISORDER

  1. Autism spectrum disorder.
    Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J.
    Lancet. 2018 Aug 11;392(10146):508-520. doi: 10.1016/S0140-6736(18)31129-2. Epub 2018 Aug 2. Review.
  2. Emerging Roles for the Gut Microbiome in Autism Spectrum Disorder.
    Vuong HE, Hsiao EY.
    Biol Psychiatry. 2017 Mar 1;81(5):411-423. doi: 10.1016/j.biopsych.2016.08.024. Epub 2016 Aug 26. Review.
  3. Pharmacogenomics of autism spectrum disorder.
    Brown JT, Eum S, Cook EH, Bishop JR.
    Pharmacogenomics. 2017 Mar;18(4):403-414. doi: 10.2217/pgs-2016-0167. Epub 2017 Feb 22. Review.

SCHIZOPHRENIA

  1. Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Kardashev A, Ratner Y, Ritsner MS.
    Clin Schizophr Relat Psychoses. Spring 2018;12(1):31-41. doi: 10.3371/CSRP.KARA.070415. Epub 2015 Jul 28.
  2. New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis.
    Yang AC, Tsai SJ.
    Int J Mol Sci. 2017 Aug 3;18(8). pii: E1689. doi: 10.3390/ijms18081689. Review.
  3. Schizophrenia.
    Owen MJ, Sawa A, Mortensen PB.
    Lancet. 2016 Jul 2;388(10039):86-97. doi: 10.1016/S0140-6736(15)01121-6. Epub 2016 Jan 15. Review.
  4. Effect of L-theanine on glutamatergic function in patients with schizophrenia.
    Ota M, Wakabayashi C, Sato N, Hori H, Hattori K, Teraishi T, Ozawa H, Okubo T, Kunugi H.
    Acta Neuropsychiatr. 2015 Oct;27(5):291-6. doi: 10.1017/neu.2015.22. Epub 2015 Apr 21.
  5. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.
    Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S.
    Clin Neuropharmacol. 2013 Nov-Dec;36(6):185-92. doi: 10.1097/WNF.0000000000000001.

NEURAXPHARM ITALY

ricerca, sviluppo e commercializzazione di molecole innovative per la prevenzione e il trattamento delle patologie in ambito Psichiatrico, Neurologico e Geriatrico

© NEURAXPHARM ITALY • P. IVA 02062550443 CONDIZIONI DI UTILIZZO PRIVACY POLICY COOKIE POLICY